Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

lion, or $0.09 per diluted share. The net loss for the quarter ended March 31, 2007, included employee stock-based compensation expense of $3.0 million, or $0.06 per diluted share.

Net Revenue from Unconsolidated Joint Business

In the first quarter of 2008, Onyx reported net revenue from unconsolidated joint business of $37.7 million compared to $3.0 million for the first quarter of 2007. The net revenues from unconsolidated joint business were based on total Nexavar sales of $151.9 million in the first quarter of 2008. The increase in net revenue from unconsolidated joint business over prior year is due to the increase in Nexavar revenue recognized by Bayer offset by the increase in combined commercial and research and development expenses for Nexavar. The calculation of this line item is shown in the table following the Condensed Statement of Operations.

Operating Expenses

In the first quarter of 2008, Onyx recorded research and development expenses of $7.4 million, an increase of $1.9 million over the first quarter of 2007. The increase in expenses incurred in the first quarter of 2008 was primarily due to higher costs incurred for the breast cancer program. Research and development expenses included $0.6 million of employee stock-based compensation for the first quarter of 2008 and $0.5 million for the first quarter of 2007.

In the first quarter of 2008, selling, general and administrative expenses were $19.8 million, an increase of $6.7 million over the first quarter of 2007. The increase in selling, general and administrative expenses was primarily due to increases in stock-based compensation, other employee-related expenses and increased marketing expense to support Nexavar. Selling, general and administrative expenses included $4.6 million of employee stock-based compensation in the first quarter of 2008 compared to $2.5 million for the first quarter of 2007.

Cash, Cash Equivalents and Marketable Securities

As
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Toronto, Canada (PRWEB) July 30, 2014 ... been available in health services research for a ... an upswing in interest regarding the use of ... actual practice conditions. , By combining today’s powerful ... in the digital era, ‘big data’ holds significant ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... Preparing for The Joint,Commission survey process within the ... internal services used to support patient,care, including all ... a result, a,healthcare institution must be prepared for ... direction and to involve any staff member. EH&E ...
... England, June 10 The Board of,Directors of ... global specialty,biopharmaceutical company, announces today that Graham Hetherington ... Executive Board Director on,1st July 2008., Graham ... senior financial,roles having most recently held positions as ...
... Calif., June 10 ,CryoLife, Inc. (NYSE: CRY ), ... that they have received a CE Mark for the ... endoscopic,browplasty or brow lift, a reconstructive plastic surgery procedure. ... in the European Community,(EU)., BioGlue will be distributed ...
Cached Biology Technology:White Paper Helps Hospitals Prepare Staff for Joint Commission Environment of Care Interview Sessions 2Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire 2Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire 3CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 2CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 3CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 4
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... A team of biologists, led by Clemson University associate ... marine pest that will pave the way for novel ... bio-adhesives for medical and industrial applications. , The team,s ... examined the last larval stage of barnacles that attaches ... natural, possibly polymeric material that acts as an underwater ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... almost unbearably complex. Humans and mice, frogs and flies ... sequences during their relentless march from embryo to death. ... proteins behind the genomic wizard,s screen have a powerful ... the Stanford University School of Medicine. Until now, ...
... Researchers from the University of Leeds, UK, the Charit ... for Molecular Medicine (MDC) in Berlin, Germany, have discovered ... studies have identified how ,junk, DNA promotes the growth ... Constanze Bonifer (University of Leeds) and Dr Stephan Mathas ...
... , VANCOUVER, BRITISH COLUMBIA Although there is no ... in several genes are associated with the developmental brain ... may be involved with autism. Investigators will present ... Academic Societies (PAS) annual meeting in Vancouver, British Columbia, ...
Cached Biology News:New Stanford tool enables wider analyses of genome 'deep sequencing' 2New Stanford tool enables wider analyses of genome 'deep sequencing' 3'Junk DNA' drives cancer growth 2Study adds to evidence that autism has genetic basis 2
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Reacts with methylated DNA from plants and vertebrates...
Biology Products: